To ensure the integrity of DTX and HuR CRISPR, we engineered versatile nanoparticles coated with multifunctional peptides and acidic tumor microenvironment (TME)-sensitive peptides, thereby establishing a promising delivery system for the combined therapy of DTX and HuR CRISPR. The gene discussed is ELAVL1; the disease is neoplasm.